Single application of high-intensity focused ultrasound as a first-line therapy for clinically localized prostate cancer: 5-year outcomes.

Link:
Autor/in:
Erscheinungsjahr:
2012
Medientyp:
Text
Schlagworte:
  • Humans
  • Male
  • Aged
  • Middle Aged
  • Aged, 80 and over
  • Treatment Outcome
  • Retrospective Studies
  • Kaplan-Meier Estimate
  • Prostate-Specific Antigen/blood
  • Prostatectomy/methods/mortality
  • Prostatic Neoplasms/blood/mortality/pathology/*therapy
  • Salvage Therapy/methods/mortality
  • Ultrasound, High-Intensity Focused, Transrectal/*methods/mortality
  • Humans
  • Male
  • Aged
  • Middle Aged
  • Aged, 80 and over
  • Treatment Outcome
  • Retrospective Studies
  • Kaplan-Meier Estimate
  • Prostate-Specific Antigen/blood
  • Prostatectomy/methods/mortality
  • Prostatic Neoplasms/blood/mortality/pathology/*therapy
  • Salvage Therapy/methods/mortality
  • Ultrasound, High-Intensity Focused, Transrectal/*methods/mortality
Beschreibung:
  • Study Type--Therapy (case series) Level of Evidence 4. What's known on the subject? and What does the study add? High-intensity focused ultrasound (HIFU) therapy has been proposed for the treatment of localized prostate cancer (PCa) for all risk levels of tumour recurrence. The study adds data on the efficacy of a single HIFU application in the treatment of PCa with different risks of recurrence. Durable cancer control was achieved in 81.7% of patients with low-risk disease, with rates of efficacy declining in intermediate- and high-risk tumours. The data suggest that the principal domain for minimal invasive HIFU should be low-risk disease.
  • Study Type--Therapy (case series) Level of Evidence 4. What's known on the subject? and What does the study add? High-intensity focused ultrasound (HIFU) therapy has been proposed for the treatment of localized prostate cancer (PCa) for all risk levels of tumour recurrence. The study adds data on the efficacy of a single HIFU application in the treatment of PCa with different risks of recurrence. Durable cancer control was achieved in 81.7% of patients with low-risk disease, with rates of efficacy declining in intermediate- and high-risk tumours. The data suggest that the principal domain for minimal invasive HIFU should be low-risk disease.
Lizenz:
  • info:eu-repo/semantics/restrictedAccess
Quellsystem:
Forschungsinformationssystem des UKE

Interne Metadaten
Quelldatensatz
oai:pure.atira.dk:publications/ab48dd37-792f-4d1d-85e7-587530e885a7